Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$24.62 - $32.44 $320 - $421
-13 Reduced 11.61%
99 $3,000
Q2 2022

Aug 08, 2022

BUY
$19.74 - $29.01 $1,519 - $2,233
77 Added 220.0%
112 $3,000
Q1 2022

May 10, 2022

BUY
$26.68 - $41.63 $933 - $1,457
35 New
35 $1,000
Q4 2021

Feb 11, 2022

SELL
$33.67 - $43.44 $2,222 - $2,867
-66 Closed
0 $0
Q3 2021

Nov 08, 2021

SELL
$30.65 - $35.68 $127,657 - $148,607
-4,165 Reduced 98.44%
66 $2,000
Q2 2021

Aug 09, 2021

SELL
$34.33 - $44.68 $9,028 - $11,750
-263 Reduced 5.85%
4,231 $146,000
Q1 2021

Apr 28, 2021

BUY
$40.81 - $53.88 $182,094 - $240,412
4,462 Added 13943.75%
4,494 $193,000
Q4 2020

Feb 09, 2021

SELL
$36.63 - $47.63 $110,988 - $144,318
-3,030 Reduced 98.95%
32 $1,000
Q3 2020

Nov 02, 2020

SELL
$30.09 - $43.02 $152,255 - $217,681
-5,060 Reduced 62.3%
3,062 $118,000
Q2 2020

Aug 11, 2020

BUY
$27.76 - $33.42 $224,967 - $270,835
8,104 Added 45022.22%
8,122 $264,000
Q1 2020

May 15, 2020

SELL
$20.69 - $37.79 $123,084 - $224,812
-5,949 Reduced 99.7%
18 $0
Q4 2019

Feb 13, 2020

BUY
$32.75 - $41.43 $195,419 - $247,212
5,967 New
5,967 $206,000
Q2 2019

Aug 05, 2019

SELL
$29.6 - $40.93 $13,112 - $18,131
-443 Closed
0 $0
Q1 2019

Apr 16, 2019

SELL
$27.85 - $38.09 $68,705 - $93,968
-2,467 Reduced 84.78%
443 $14,000
Q4 2018

Jan 17, 2019

BUY
$32.39 - $42.05 $30,090 - $39,064
929 Added 46.9%
2,910 $105,000
Q3 2018

Nov 02, 2018

SELL
$35.69 - $47.65 $19,665 - $26,255
-551 Reduced 21.76%
1,981 $0
Q2 2018

Jul 24, 2018

BUY
$28.41 - $42.41 $71,934 - $107,382
2,532 New
2,532 $0
Q1 2018

May 03, 2018

SELL
$21.18 - $33.78 $953 - $1,520
-45 Closed
0 $0
Q4 2017

Feb 02, 2018

SELL
$19.29 - $24.83 $790 - $1,018
-41 Reduced 47.67%
45 $1,000
Q3 2017

Oct 20, 2017

BUY
$19.61 - $23.35 $1,686 - $2,008
86
86 $2,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.09B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.